NT-175 is under clinical development by Neogene Therapeutics and currently in Phase I for Metastatic Breast Cancer. According to GlobalData, Phase I drugs for Metastatic Breast Cancer have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NT-175’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NT-175 overview
NT-175 is under development for the treatment of non-small cell lung cancer, head and neck squamous cell carcinoma, metastatic colorectal carcinoma, metastatic adenocarcinoma of pancreas, metastatic breast cancer, and other solid tumors. The therapeutic candidate comprises autologous T-cells genetically engineered to express HLA-A*02:01-restricted T cell receptor (TCR) targeting cells expressing TP53 R175H. It is administered through intravenous route.
Neogene Therapeutics overview
Neogene Therapeutics, a subsidiary of AstraZeneca Plc, operates as a pre-clinical stage biotechnology company that is engaged in the development, and manufacturing T cell receptor therapies for solid cancers. The company is headquartered in Santa Monica, California, the US.
For a complete picture of NT-175’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.